OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
3
Results
Show all
Save search
Copy query
Show results for
Unknown
(3)
Publication Date
Release Date
2024
(2)
2023
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.
Not available
S-EPMC11014903
|
biostudies-literature
Cite
Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial.
Not available
S-EPMC11381616
|
biostudies-literature
Cite
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19.
Not available
S-EPMC10150320
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
